Phase 1 IC Clinical Trials
2,762 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 2,762 trials
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Lupus Erythematosus, Systemic
AstraZeneca150 enrolled18 locationsNCT06897930
Recruiting
Phase 1Phase 2
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
Epileptic Encephalopathy
Institut de Recherches Internationales Servier20 enrolled16 locationsNCT07227857
Recruiting
Phase 1Phase 2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals181 enrolled25 locationsNCT07190300
Recruiting
Phase 1Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Sickle Cell Disease
Novartis Pharmaceuticals161 enrolled3 locationsNCT06546670
Recruiting
Phase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled31 locationsNCT06465069
Recruiting
Phase 1Phase 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled5 locationsNCT07288359
Recruiting
Phase 1
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting
Phase 1Phase 2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
National Cancer Institute (NCI)160 enrolled1 locationNCT06303193
Recruiting
Phase 1
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled7 locationsNCT07458347
Recruiting
Phase 1
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
dry eye syndromeSystemic Lupus Erythematosus
AbbVie36 enrolled6 locationsNCT06977724
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled5 locationsNCT07397338
Recruiting
Phase 1
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC)Carcinoma, AdrenocorticalCarcinoma, Adrenal Cortical+2 more
National Cancer Institute (NCI)32 enrolled1 locationNCT06487481
Recruiting
Phase 1Phase 2
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive
M.D. Anderson Cancer Center40 enrolled2 locationsNCT06308588
Recruiting
Phase 1
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)66 enrolled6 locationsNCT05687136
Recruiting
Phase 1
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
Polycystic Ovary Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)100 enrolled1 locationNCT03049462
Recruiting
Phase 1Phase 2
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Institut de Recherches Internationales Servier52 enrolled38 locationsNCT06501625
Recruiting
Phase 1Phase 2
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
AstraZeneca40 enrolled15 locationsNCT07228364
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled128 locationsNCT05006716